GHIC invests in Verge HealthTech Fund II through the Catalytic Health Investment Platform

SINGAPORE / NEW YORK, NY, 24 July 2025: GHIC is pleased to announce its investment in Verge HealthTech Fund II, a global venture capital fund investing in early-stage technologies that enable affordable healthcare access for underserved populations worldwide. GHIC has invested through the Catalytic Health Investment Platform (CHIP), a partnership with the Government of Germany through its Public Development Bank KfW to accelerate the development of public health technologies and products to improve global health.

Verge HealthTech Fund II is focused on companies developing scalable technologies with the potential to transform healthcare affordability, access and efficiency. The fund’s investments target both cutting-edge deep tech applications in healthcare through AI and data, next-generation diagnostics, and breakthrough smart devices, as well as opportunities to transform delivery using digital health platforms, digital therapeutics and healthcare software-as-a-service models.

Headquartered in Singapore, Verge’s global team across Asia and Europe brings diverse investment experience in 24 countries. The firm’s prior investments demonstrate a strong track record of impact, touching more than 25 million lives to date – over 90% in low- and middle-income countries. These include reach52, a healthcare delivery platform for underserved communities in Africa, Southeast Asia and India, Saludtools, Colombia’s leading primary care EHR provider now expanding throughout Latin America, and Doctorkoi, a digital prescribing and patient management platform for low-resource settings in Bangladesh.

Labeeb Abboud, Chairman and CEO, Global Health Investment Corporation said:

“We are pleased to support Verge’s efforts to harness the power of innovative technology to overcome barriers to healthcare. This is fully aligned with the mission of our Catalytic Health Investment Platform, and we look forward to a fruitful partnership with Verge in accelerating impact in low- and middle-income countries.”

“We are honored to have GHIC support us in our journey to transform health for millions of individuals without access to quality healthcare,” said Scarlett Chen, Managing Partner, Verge HealthTech Fund. “We believe that by investing in impactful, scalable healthtech solutions, we have the potential to create outsized impact and financial returns. Our team is enthused and grateful for the belief of GHIC and KfW in us and our mission.”

About GHIC and the Catalytic Health Investment Platform (CHIP):

GHIC, a nonprofit organization, has been investing in global health innovation for over a decade. GHIC seeks to catalyze the development of technologies to improve global health through investments in vaccines, therapeutics, diagnostics, medical devices, and other technologies to save and improve lives, by mobilizing private, public, and philanthropic capital via innovative partnership models. GHIC leverages the engagement, networks, and funding of its strategic partners and stakeholders to drive innovation, and invest in innovative health technologies for a healthier, safer world.

The Catalytic Heath Investment Platform (CHIP) is a twenty-year partnership between GHIC and the Government of Germany, through its Federal Ministry for Economic Cooperation and Development (BMZ) and KfW, to accelerate the development of public health technologies and products to improve global health. CHIP catalyzes health innovation to address the needs of underserved populations in low- and middle-income countries through investments in funds and companies as well as grant making opportunities.

Inquiries regarding the Catalytic Health Investment Platform can be directed to CHIP@ghicfunds.org.